Home > Pulmonology > ATS 2022 > Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?

Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?

Presented By
Prof. Ulrich Specks, Mayo Clinic, MN, USA
Conference
ATS 2022
Trial
Phase 3, ADVOCATE
An exploratory subgroup analysis of the phase 3 ADVOCATE trial showed that avacopan was only somewhat better than prednisone at reducing respiratory, as well as ear, nose, and throat (ENT), involvement in patients with ANCA-associated vasculitis. However, reduced glucocorticoid use in the avacopan group was a clear clinical benefit. Prof. Ulrich Specks (Mayo Clinic, MN, USA) presented the respiratory and ENT outcomes of the phase 3 ADVOCATE trial (NCT02994927) [1]. ADVOCATE was a phase 3, randomised, double-blind, double-dummy, controlled clinical study comparing the selective neutrophil C5aR inhibitor avacopan (plus prednisone-matching placebo) with prednisone (plus avacopan-matching placebo) in addition to either cyclophosphamide (followed by azathioprine) or rituximab. The trial results demonstrated the efficacy of avacopan in helping patients with ANCA-associated v...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on